(3) have reported on the prevalence of TSC1 germline mutations in 5,041 patients with breast cancer (pathogenic variants (PVs) vs. variants of uncertain significance (VUS): 0.00% vs. 0.30%) and the prevalence of TSC2 germline mutations in 5,040 patients with breast cancer (PVs vs. VUS: 0.00% vs. 1.20%). This evidence concerns the gene TSC2 and breast cancer.